The Global Health Body Sounds Warning Over Critical Lack of Weight-Loss Injections
Under one in 10 people eligible to benefit from obesity jabs including Wegovy can access them, caution the World Health Organization as it releases its inaugural advice on the drugs.
Given over a billion people worldwide now classified as obese, it is calling for broader and more equitable access to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be addressed with comprehensive and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are key barriers to widespread availability to the injections that can assist patients in reducing substantial body mass, notes the organization.
Skinny Jab Shortage
Despite the present best projected case, the supply of such drugs would only suffice for around 100 million people – less than 10% of the global need, per the WHO.
The guideline encourages countries and companies to widen availability, by approaches such as patent sharing.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026.
How Obesity Jabs Operate
The injections mimick a natural hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so people consume fewer calories.
Patients commonly start to lose weight in the initial weeks of starting on the once-weekly jabs.
Research indicates people may put most of the weight back on a year later of halting the drug, as their typical appetite come back.
To be carrying excess weight elevates your likelihood for contracting diseases, including diabetes, heart disease, brain attack, and some cancers.
Obesity affects people in countries worldwide and was associated with millions of fatalities worldwide in 2024, according to the WHO.
